Chemistry:Pegzilarginase

From HandWiki
Short description: Medication
Pegzilarginase
Clinical data
Trade namesLoargys
Other namesAEB-1102
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC1554H2492N416O463S6
Molar mass34603.84 g·mol−1

Pegzilarginase, sold under the brand name Loargys, is a medication used for the treatment of hyperargininemia.[1][2]

The most common side effects include allergic reactions.[1]

Pegzilarginase was approved for medical use in the European Union in December 2023.[2]

Medical uses

Pegzilarginase is indicated for the treatment of arginase 1 deficiency, also known as hyperargininemia.[1][2]

Society and culture

Legal status

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Loargys, intended for the treatment of hyperargininemia.[1] The applicant for this medicinal product is Immedica Pharma AB.[1] Pegzilarginase was approved for medical use in the European Union in December 2023.[2]

Brand names

Pegzilarginase is the international nonproprietary name.[3]

Pegzilarginase is sold under the brand name Loargys.[1]

References

  1. Jump up to: 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "Loargys EPAR". 14 July 2016. https://www.ema.europa.eu/en/medicines/human/EPAR/loargys.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. Jump up to: 2.0 2.1 2.2 2.3 2.4 "Loargys Product information". 18 December 2023. https://ec.europa.eu/health/documents/community-register/html/h1774.htm. 
  3. "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information 32 (1). 2018. 

External links